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It is well established that allo-transplantation is associated with the transfer of infectious 
agents ; indeed management of transplant infectious risk developed in parallel with other 
developments in the field.  Allo-transplantation has its inherent specific infection-related 
problems, and the citeria for use of infected organs is changing due to the lack of donors, 
the improvements in anti-viral agents and testing tools. Based on these developments, the 
use of organs with either ‘high’  or ‘increased’ infectious risk  has become more acceptable 
[1, 2]. 
[1, 2]. We are aware that there are animal reservoirs of human disease leading to zoonotic 
infections, and pigs as donors in xenotransplantation are no exception.  Considering 
allotransplantation and the other safety considerations voiced by the FDA at the IXA 2017 
symposium [3] it is paramount that pathogens present drive the risk assessment and safety 
for the recipient.  With this in mind, there are criteria that need to be met in order to ensure 
the safety of any recipient from potential pathogens present in a xenograft .   
Two main issues are required to be addressed for safety; source donor animal testing and 
recipient monitoring.  For our purposes, we report on the work we have done to address a 
number of safety issues in relation to islet cell transplantation and some of the issues raised 
in relation to the updated FDA guidance for xenotransplantation [4]  
There are numbers of documents providing guidance including the consensus statements by 
experts published in the Xenotransplantation journal and the FDA updated guidance 
released in December 2016 mentioned above; it is clear that testing for pathogens is a 
primary objective for safety [5-7].  This includes the demonstration of a lack of 
pathogens/contamination at several points in the product preparation process.  Due to 
conflicting issues with the concept of a specified ‘list’, considerations should be given with 
respect to testing; this includes the geographical location of the donor animals, the product 
being tested, the degree of immune suppression and the availability of validated diagnostics 
.  Use of donors reared in barrier facilities under designated pathogen-free conditions 
should be agreed with the above in mind, and this is required to reduce risk, as not all 
pathogens of concern in xenotransplantation are part of standard testing [8].  It should be 
noted that most of these ‘lists’ of pathogens for testing and/or exclusion are created by 
experts in the field, from advisory boards to clinical application with specific purposes in 
mind [7, 9-11]. For example, the  specific exclusion list from the donor animals  used by the 
Living Cell Technologies (now Diatranz Otsuka Ltd) for clinical trials in islet 
xenotransplanrtation [11, 12] is very different from  the  4 checkpoint programme for 
comprehensive testing throughout the manufacturing process of encapsulated islets 
including the final product [10]. 
One area of controversy which continues to be discussed is the transfer of infectious 
microorganisms to the recipient, but it is clear that many can be eliminated via the 
husbandry process.  The risk associated with PERV has also been debated with regard to the 
potential of infection in vivo that appears much less than initially thought; a number of 
publications have questioned whether PERV is indeed even a risk anymore [13, 14] Indeed, 
recently there has been a call for regulatory authorities to reconsider their guidance with 
respect to this evidence [15].  Given recent publications that have inactivated PERV in cells 
and pigs using CRISPR-Cas9 technology [16, 17], this raises the question as to why 
inactivation would indeed be required if risk is low? Inactivation/inhibition is seen as an 
additional strategy for safety [13] but could this be another reconsideration with respect to 
the difference between cell xenotransplantation and organ xenotransplantation? The final 
point to make is, given that editing requires constitutive expression over a period of several 
weeks, does this introduce another risk , i.e., activation of other genes during this period?  
How is this to be evaluated ?  This  approach should be balanced with the fact that PERV has 
not been transferred in vivo with the selected pig lines used [16, 18].   
We have known and unknown infectious agents to consider, so to try to address all aspects 
of the guidance and these testing requirements. Under the Xenoislet programme (EU FP7 
project number 601827 – co-ordinator P Gianello) we have adressed the question of safety 
in donor animals and encapsulated islet cells by pathogen testing at the respective 
checkpoints.  The aim was  to identify suitable animals to establish a founder line for islet 
xenotransplantaton by 1) assessing  the pathogen status of all source animals; advise 
selection of breeding animals that are free from designated pathogens and meet the criteria 
for PERV status, and 2) product testing, to evaluate the level of protection from pathogen 
contamination offered by the alginate macroencapsulation device (MCD), to evaluate 
pathogen status of the product and to develop sensitive and reproducible assays. 
We identified 9 animals out of 392 analysed that met criteria previously described and 
would be suitable to take forward ; PERV-C env PCR  negative, low PERV-A and PERV-B copy 
number (<30 PCR copies per genome) and no  in vitro transmission during cell culture with 
both human HEK293 and ST-IOWA cells.  4/9 animals were found positive for porcine 
Cytomegalovirus, however, if animals are to be cloned, then this virus is not an issue when a 
skin biopsy is utilised; in additon, husbandry procedures involving hysterotomy derivation of 
the offspring is a suitable approach to eliminate this pathogen [6].   Looking at the pathogen 
status in the cell product, PERV RNA was located the endocrine fraction of the pancreas and 
neonatal islets had signficantly lower levels of PERV RNA than adult islets [19].  In addition, 
PERV RNA expression did not change over the neonatal islet cell 8 day-culture and 
maturation period [19].  This raises questions as to whether PERV replication is restricted in 
some way in islet cells compared to PBMC. We also tested the islet cells for other pathogens 
and found them to be negative compared to the positive findings in the donor animal in 
both neonatal and adult derived peripheral blood mononuclear cells (PMBC) [20]. 
Finally, we investigated the possibility of the prevention of PERV release from the alginate-
based MCD.  Our preliminary study suggests that the alginate is sufficient to significantly 
reduce PERV transmission and may be a suitable barrier for other pathogens too [21].  PERV 
transmission from free and encapsulated islet cells was assessed using the animal model in 
nonhuman primates (NHP).  We understand the limitations of this model due to the lack of 
receptors to fully demonstrate PERV transmission, however, interestingly, we found that in 
animals receiving free islets, we could detect porcine micro-chimerism but not in those 
receiving encapsulated islets (C Crossan; unpublished data). 
In summary, with respect to islet cells, neonatal pig islets have lower levels of PERV RNA 
than adult islets; the mechanism is unknown.  Pathogens present in the donor animals do 
not appear to be present in islets and there are indications that the alginate MCD is 
protective against the release of PERV in vitro.  Irrespective of the multi-level testing 
strategy chosen, testing of the end product is an important requirement given differences 
observed.  As encapsulation would also reduce the use of immunosuppression, can 
encapsulated islets be considered low risk? Does this data support moving islets to the 
clinic? 
Finally, we need to consider testing in recipients.  PERV testing for recipients as defined by 
FDA CBER 2016 section X:F [4]is as follows: 
1) PCR of recipient’s PBMC for PERV DNA sequence, 2) serologic analysis for PERV‐specific 
antibodies, and 3) assays capable of detecting plasma virions, such as RT-PCR for detection 
of viral RNA or highly sensitive methods for detection of RT activity.  Sensitive assays are not 
available commercially, and consistency for testing is required alongside validated assays 
and by recognised laboratories using suitable donor and archived samples.  In addition to 
PERV, we need to think about the evaluation of infectious syndromes in recipient; including  
exclusion of common infections, assessment of other recipients from same donor source or 
herd, evaluation of contacts and investigation for organisms not previously associated with 
clinical syndromes in humans.  This can be followed by the use of questionnaires [7].  
It is suggested that testing is based on the Precautionary Principle: “The risk of xenogeneic 
infection is generally thought to be low but the deployment of appropriate procedures and 
assays should not wait until a  risk is confirmed”.[7]  However this is not a scientifically 
based approach. With respect to PERV, the evidence does indeed demonstrate the risk is 
minimal. 
Pathogen contamination of porcine derived products still in use have yet to reveal any 
adverse events related to those products.  There are a number of in vivo trials to date, even 
though the emerging risk is still unclear there is no evidence of cross species infection via 
known micro-organisms [11, 22-25].  In addition, in the event of detection, PERV is 
susceptible to anti-virals[26]. Given the current status of xenotransplantation, the risk of 
transmission appears to be low  and not greater than that seen for allo-transplantation: pre-
clinical screening would reduce the risk further suggesting we may have already met the 
stringency criteria for ‘first-in-man’ studies. In fact, this is a misnomer as we already have 
seen clinical trials utilsing pig tissues.  However, the risk is not zero.  So to conclude, we have 
defined pathogens of risk as suggested by experts in the field of xenotransplantation but 
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